About Pragya Pandey

Pragya is an equity research analyst and financial journalist with a passion for investing. In college she majored in finance and is currently pursuing the CFA program and is a Level II candidate.

When analyzing stocks, Pragya takes a fundamental approach and focuses on measuring a company's intrinsic value. Her goal is to help retail investors create successful portfolios to achieve financial success.


Recent Articles By Pragya Pandey

: ITUB |  News, Ratings, and Charts

Is Now a Good Time to Buy Brazilian Bank Stocks?

The performance by banks worldwide has been sluggish since the onset of the COVID-19 pandemic last year. Slower loan growth, declining margins, and growing debt delinquencies have weighed on banks’ short-term earnings projections. Given this backdrop, is it worth betting on Brazilian banking stocks Itau Unibanco (ITUB) and Banco Bradesco (BBD) now? Read on to learn our view.
: IT |  News, Ratings, and Charts

If You Like High-Quality Stocks, Check Out Gartner

Leading research and advisory company Gartner (IT) has outperformed the broader market because investors remain bullish on its growth prospects. Given the company’s solid fundamentals and favorable analyst estimates, we think investors seeking to invest in a high-quality stock could consider IT now. Read on.
: MDB |  News, Ratings, and Charts

Is MongoDB a Good Database Management Stock to Own?

Database management company MongoDB (MDB) has gained importance on the back of rapid digitization and technological transformation. However, rising Treasury yields have raised investor concerns about the tech industry's growth prospects, leading the company's shares to decline 12.7% in price over the past month. So, considering MDB's underwhelming financials and premium valuation, is it worth betting on the stock now? Read on to learn more.
: YOU |  News, Ratings, and Charts

Down 43% Over the Past Month, Should You Scoop Up Shares of Clear Secure?

The shares of Clear Secure (YOU) gained nearly 30% in price on its stock market debut on June 30, 2021. However, the stock has been retreating since. So, considering the company’s poor fundamentals and profitability, is it worth adding the stock to one’s portfolio? Let’s find out.
: CHWY |  News, Ratings, and Charts

Do Shares of Chewy Deserve a Place in Your Portfolio?

Online pet products retailer Chewy Inc. (CHWY) saw solid sales growth amid the pandemic as consumers eschewed brick-and-mortar stores. However, given that the company is currently struggling with supply chain bottlenecks and rising costs, which impacted its earnings in its last reported quarter, is it worth adding the stock to one's portfolio now? Let's find out.
: COUP |  News, Ratings, and Charts

Beware of These 2 Recently Downgraded Software Stocks

The software industry has been one of the fastest-growing industries over the past year. But not all software stocks have been able to benefit from the industry tailwinds and strengthen their fundamentals. Given the growing competition in the industry, we think it could be wise to avoid Coupa Software (COUP) and Sumo Logic (SUMO), which analysts have recently downgraded. Read on.
: IPG |  News, Ratings, and Charts

Does The Interpublic Group of Companies Deserve a Place in Your Portfolio?

The shares of leading marketing solutions company The Interpublic Group of Companies (IPG) have rallied 55.1% in price year-to-date. The company has achieved solid top-line growth across all its segments due to increasing consumer demand for digital media solutions. Given the company's solid fundamentals and its shares’ discounted valuation, we think it could be wise to add IPG to one's portfolio now. Let’s discuss.
: ESPR |  News, Ratings, and Charts

2 Biotech Stocks Under $10 Wall Street Predicts Will Triple in Price

An increasing focus on integrating advanced technologies into research efforts to generate viable drugs for treating various critical ailments, and growing demand for therapies from an aging population, should boost the biotech industry's growth. Given this backdrop, Wall Street analysts expect two low-priced biotech stocks—Esperion Therapeutics (ESPR) and CTI BioPharma (CTIC)—to deliver exceptional returns in the near term. Please read on for an explanation.
: NEE |  News, Ratings, and Charts

Is NextEra Energy a Good Clean Energy Stock to Buy?

Leading clean energy company NextEra Energy (NEE) is expected to generate substantial long-term gains as governments worldwide strive to increase the usage of renewable energy to combat the rising threat of climate change. However, considering the growing competition in this space and NEE’s mixed profit margins, is it worth adding the stock to one’s portfolio? Read on. Let’s find out.
: TDOC |  News, Ratings, and Charts

2 Beaten-Down Stocks Wall Street Analysts Believe Can Rally Significantly in 2022

Despite the Fed's announcement that it may speed up its tapering of bond purchases, and rising omicron variant fears, analysts remain optimistic about the market's prospects in 2022. Given this sentiment, Wall Street analysts expect two beaten-down stocks, Teladoc Health (TDOC) and Peloton Interactive (PTON), to rally significantly in 2022. So, we think it could be worth adding these stocks to one’s watchlist. Read on for a more detailed discussion.
Page generated in 1.4258 seconds.